Business Development Lead
Celentyx, United Kingdom
Dr Mark Bryant leads Celentyx’s business development activities. The company specialises in bringing human tissue based novel technologies to the pharmaceutical market with relevance to immuno-oncology, inflammation, fibrosis and neuroinflammation. With a PhD in wound healing, Dr Bryant’s early research focused on the role of inflammation upon healing and scarring. Research at GSK identified the role of the transcription factor egr -1 in these processes, resulting in a novel gene therapy programme for chronic wound healing. For the last 25 years, he has helped develop and commercialise a broad range of technologies including novel drug discovery platforms, safety pharmacology assays, inflammation models and stem cell derived technologies.